In acute ischemic stroke, day 90 mRS scores of 0-2 occurred in 93.64% with initial intravenous Cortexin versus 86.50% with intramuscular Cortexin.
In plain wordsIn stroke patients, the share with a favorable disability score at day 90 was 93.64% with initial intravenous Cortexin and 86.50% with intramuscular Cortexin.
- Outcome
- Direction not reportedModified Rankin score 0-2 at day 90
- Study
n = 490
- Comparator
- intramuscular Cortexin in both courses
- Outcome group
- Exercise and physical function · Nervous system and cognition
- Studied dose
- 10 mg twice daily · intravenous or intramuscular in the first course, intramuscular in the second course · two courses of 10 days eachAs given in this study (human).
Measurements
- mRS 0-2
- 93.64%
- initial intravenous Cortexin at day 90
- mRS 0-2
- 86.5%
- intramuscular Cortexin at day 90
Source sentences
The proportion of patients who reached 0-2 on the mRS scale on day 90 was 93.64% and 86.50% in the groups receiving Cortexin intravenously and intramuscularly, respectively.
4 context sentences(design, population, supporting numbers)
A multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted.
The study included 490 patients with acute IS, male (54.1%) and female (45.9%) aged from 30 to 80 years (average age 63.97+8.5 years), divided into 2 groups: 1 - main (Cortexin intravenous form, n=246), 2 - comparison (Cortexin intramuscular form, n=244).
In the first course: Group 1 - Cortexin 10 mg IV and placebo IM 2 times a day; Group 2 - Cortexin 10 mg IM and placebo IV 2 times a day.
After 10 days, patients in both groups received a second course of therapy with Cortexin 10 mg, IM, 2 times a day, 10 days.